PREPARATION AND IN VIVO EVALUATION OF EUDRAGIT® L100/EUDRAGIT® NM 30D ENTERIC GRANULES CONTAINING DICLOFANAC SODIUM: ANTI-INFLAMMATORY AND ULCEROGENIC ACTIVITY

Extended-release granule formulations containing diclofenac sodium were prepared by wet granulation of Eudragit® L100 and Eudragit® NM 30D polymers. The drug release was examined in phosphate buffer (pH 6.8). The formulations allowed 100 % released drug by 720 min. The granules were evaluated with respect to their anti-inflammatory and ulcerogenic activity in rats. Eudragit® L100/Eudragit® NM 30D granules provide a significant and prolonged anti-inflammatory effect and also significantly reduce (52-74 %) the gastric lesion index.

[1]  G. Scriba.  Sean C. Sweetman (Ed.): Martindale: The Complete Drug Reference , 2011 .

[2]  H. Frijlink,et al.  Pulsatile drug delivery to ileo-colonic segments by structured incorporation of disintegrants in pH-responsive polymer coatings. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[3]  J. Wallace,et al.  NSAID-induced gastrointestinal damage and the design of GI-sparing NSAIDs. , 2008, Current opinion in investigational drugs.

[4]  B. S,et al.  Hollow microspheres of diclofenac sodium - a gastroretentive controlled delivery system. , 2008, Pakistan journal of pharmaceutical sciences.

[5]  S. Chandran,et al.  Design and evaluation of pH modulated controlled release matrix systems for colon specific delivery of indomethacin. , 2008, Pharmazie.

[6]  G. Van den Mooter,et al.  Comparative evaluation of interpolyelectrolyte complexes of chitosan with Eudragit L100 and Eudragit L100-55 as potential carriers for oral controlled drug delivery. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  S. Nazzal,et al.  Novel use of Eudragit NE 30D/Eudragit L 30D-55 blends as functional coating materials in time-delayed drug release applications. , 2008, International journal of pharmaceutics.

[8]  Alan B. Watts,et al.  The manufacture and characterisation of hot-melt extruded enteric tablets. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  P. Mura,et al.  Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets. , 2005, Farmaco.

[10]  Shuichi Suzuki,et al.  Analgesic Action of a Sustained Release Preparation of Diclofenac Sodium in a Canine Urate-Induced Gonarthritis , 2001 .

[11]  Maruf Ahmed,et al.  Preparation and Stability Study of Diclofenac Sodium Suppositories , 2000 .

[12]  Y. Tando,et al.  Pancreatic dysfunction and treatment options. , 1998, Pancreas.

[13]  A. Hirschfelder.  THE UNITED STATES PHARMACOPEIAL CONVENTION , 1930 .

[14]  S. Jayaprakash,et al.  Preparation and evaluation of biodegradable microspheres of methotrexate , 2009 .

[15]  Xiao-le Qi,et al.  [Preparation of tablets containing enteric-coated diclofenac sodium pellets]. , 2008, Yao xue xue bao = Acta pharmaceutica Sinica.

[16]  M. D'souza,et al.  Formulation and evaluation of albumin microspheres and its enteric coating using a spray-dryer. , 2008, Journal of microencapsulation.

[17]  N. Barakat,et al.  Diclofenac sodium loaded-cellulose acetate butyrate: effect of processing variables on microparticles properties, drug release kinetics and ulcerogenic activity. , 2008, Journal of microencapsulation.

[18]  H. Gul,et al.  Anti-inflammatory activity of bis(3-aryl-3-oxo-propyl)methylamine hydrochloride in rat. , 2007, Biological & pharmaceutical bulletin.

[19]  Z. Halıcı,et al.  Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats. , 2007, Journal of pharmacological sciences.

[20]  F. Atyabi,et al.  Ion-exchange, an Approach to Prepare an Oral Floating Drug Delivery System for Diclofenac , 2004 .

[21]  W. M. Heller,et al.  The United States Pharmacopeial Convention, Inc , 1977 .